NASDAQ · Biotechnology

Fulcrum Therapeutics, Inc. (FULC) Stock

$3.77 +0.53% NASDAQ: FULC Healthcare

Valuation

MetricValue
Price$3.77
Market Cap$287.64M
P/E Ratio-3.05
P/B Ratio0.91
P/S Ratio0.00
EPS (TTM)$-1.18
52-Week High$15.74
52-Week Low$2.83
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-28.54%
ROA-26.24%
ROCE-27.62%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio27.46

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$6.0M$3.0M$80.0M$0
Operating Profit$-81.0M$-113.0M$-111.0M$-22.0M$-85.0M
Net Profit$-81.0M$-110.0M$-97.0M$-10.0M$-75.0M
EPS$-2.22$-2.35$-1.59$-0.16$-1.18
Op Margin-423.0%-1774.8%-3945.2%-27.4%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$235.0M$227.0M$258.0M$261.0M$366.0M
Total Liabilities$23.0M$28.0M$23.0M$18.0M$17.0M
Cash$35.0M$35.0M$26.0M$58.0M$198.0M
Borrowings$0$13.0M$11.0M$9.0M$6.0M

Latest News

Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit Simply Wall St. · Jun 27, 2026 A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring Simply Wall St. · Jun 5, 2026 Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks · Jun 5, 2026 FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End Zacks · Jun 3, 2026 JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight MT Newswires · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-78.0M$-97.0M$-91.0M$-2.0M$-60.0M
Investing Cash Flow$-131.0M$10.0M$-37.0M$32.0M$30.0M
Financing Cash Flow$4.0M$4.0M$1.0M$0$0
Net Cash Flow$-22.0M$0$-10.0M$33.0M$139.0M
Free Cash Flow$-80.0M$-99.0M$-91.0M$-2.0M$-60.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-8.05
EV / EBITDA-3.08
FCF Yield-23.49%
Quick Ratio31.35
Interest Coverage0.00
Return 1Y-52.47%
Return 3Y0.53%
Return 5Y-61.65%

Ownership

Insiders Held3.83%
Institutions Held126.06%
Institutions Float Held131.08%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC6,561,1112026-03-31
RA Capital Management, L.P.6,053,9602026-03-31
Blackrock Inc.5,390,5932026-03-31
TCG Crossover Management, LLC5,250,0002026-03-31
Braidwell LP 3,134,9222026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is led by CEO Alexander C. Sapir, employs 45 people, headquartered in US, publicly traded since 2019.

Fulcrum Therapeutics, Inc. (FULC) stock trades at $3.77 with a market capitalization of $287.64M. The stock is valued at a price-to-earnings (P/E) ratio of -3.05, price-to-book of 0.91, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.83 and $15.74, and currently trades 76.0% below its 52-week high.

On profitability, Fulcrum Therapeutics, Inc. generates a return on equity (ROE) of -28.54%, return on capital employed of -27.62%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides